|
|
Post by brentie on Aug 2, 2015 8:21:32 GMT -5
|
|
|
|
Post by kc on Aug 2, 2015 11:06:18 GMT -5
Another great article with a T1 and a T2 user. Both doing great. So it's just a wait and see how fast it will be accepted by diabetics and doctors. We are 12 to 18 months to really taking off. But it will happen.
|
|
|
|
Post by mssciguy on Aug 2, 2015 11:26:44 GMT -5
Another great article with a T1 and a T2 user. Both doing great. So it's just a wait and see how fast it will be accepted by diabetics and doctors. We are 12 to 18 months to really taking off. But it will happen. Do you think some kind of smart phone app or other calculator for dosage would be helpful? Not sure how many people enjoy arithmetic any more. |
|
|
|
Post by savzak on Aug 2, 2015 11:52:20 GMT -5
ALEX: How would you describe the ideal person to take Afrezza?
BILL (T2): Anyone with diabetes could benefit from Afrezza. If you have high blood sugar, in my experience this is the easiest way for you to control it.
ANA (T1): Someone who eats three regular meals per day. It might not be for people on diets with smaller meals, or people who eat more meals per day. It’s do-able, but you have to figure out a routine and stick with it.
|
|
|
|
Post by jpg on Aug 2, 2015 12:13:14 GMT -5
Another great article with a T1 and a T2 user. Both doing great. So it's just a wait and see how fast it will be accepted by diabetics and doctors. We are 12 to 18 months to really taking off. But it will happen. Do you think some kind of smart phone app or other calculator for dosage would be helpful? Not sure how many people enjoy arithmetic any more. No. That's the beauty of Afrezza compared to regular prandial insulin. Looking at the size of a meal and a very rough estimation of carbs and knowing how you 'ballpark react to Afrezza' should be enough. |
|
|
|
Post by ezrasfund on Aug 3, 2015 8:26:58 GMT -5
Excellent article, but as always there are at least a few inaccuracies that illustrate how much more we know about Afrezza than most people.
A few comments on the interview...
"SALLY: If you could make one improvement to Afrezza what would it be?
BILL (T2): I don’t know what I would do at this point in time to correct it. I’ve found the inhaler to be extremely discreet, small, and well functioning. I don’t have any issues with it. When I first started back on Afrezza I had a small urge to cough, but I resisted because I wanted to retain the insulin. That was extremely minor, and it has essentially just disappeared.
ANA (T1): I think the inhaler. It was different from the one in the trial. We had a reusable inhaler that we cleaned and maintained. But this disposable one is smaller, and there are a certainly a lot of benefits to the one we’re using now too. The coughing is less, for example. Many of the things that were negative about it before are resolved this time around. I do wish, though, that it were something that I could reuse still and not have to get a separate prescription for the inhaler and the cartridges."
Ana was apparently on the Medtone arm of the 171 trial. I think there must be a transcription error or other misunderstanding here, as Ana should know that every box of cartridges comes with an inhaler (actually each box of 90 cartridges comes with 2 inhalers, right?).
This may a good place to mention how proud the MNKD engineers are of the inhaler design. The guy I spoke to at the ASM previously worked for a manufacturer of syringes, and he said that the dreamboat is significantly simpler (many less parts) and much less expensive to manufacture than a syringe.
ALEX: How would you describe the ideal person to take Afrezza?
BILL (T2): Anyone with diabetes could benefit from Afrezza. If you have high blood sugar, in my experience this is the easiest way for you to control it.
ANA (T1): Someone who eats three regular meals per day. It might not be for people on diets with smaller meals, or people who eat more meals per day. It’s do-able, but you have to figure out a routine and stick with it.
Here Ana's comment is right on and important IMO. Afrezza is much more suited to physically active people who eat bigger meals, than to low carb dieters who prefer salads.
Another point about those active types, notice that our tri-athlete Afrezza user is not complaining about lung issues.
|
|
|
|
Post by brentie on Aug 3, 2015 12:13:17 GMT -5
|
|
|
|
Post by ezrasfund on Aug 3, 2015 13:56:19 GMT -5
Al is responding to the idea that people on low carb diets need to be more concerned about hypos. The zero carb/no meal challenge with Afrezza showed that hypos were not a special concern.
My comment is different. People who are generally light eaters and/or on a low carb diet seem to show less dramatic improvements with Afrezza. Those who want to eat enough to be prepared for a triathlon or want to enjoy a pizza and beer with friends seem to show more dramatic improvements.
|
|
